KyungDong Pharm home
Prescription Medicines

Lucozol Cap.

Product Category
broad-spectrum antifungal drugs
Active Ingredients
Fluconazole 50mg
Appearance
A hard capsule with a blue cap and white body, containing white powder.
Reimbursement Code
648103250
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Fluconazole (USP) ................................................... 50mg
- Additives (tar coloring): Red No. 3, Blue No. 1
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: hard capsule, sodium lauryl sulfate, magnesium stearate, sodium starch glycolate, pregelatinized starch, colloidal silicon oxide

2. Efficacy/Effectiveness
1. Acute or recurrent vaginal candidiasis
2. Mucosal candidiasis, including oropharynx, esophagus, non-invasive bronchopulmonary infection, candiduria, skin mucosa, and chronic atrophic oral candidiasis (intraoral pain caused by dentures) in patients with normal immune function and patients with reduced immune function.
3. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive candidal infections (peritoneum, endocardium, lung, urinary system, etc.)
4. Cryptococcal meningitis in patients with normal immune function and patients with reduced immune function (AIDS, organ transplant patients, or other immunosuppressive therapy, etc.) and cryptococcosis in other parts of the body, such as the lungs and skin.
5. Maintenance therapy to prevent recurrence of cryptococcosis in AIDS patients
6. Prevention of fungal infections in immunocompromised patients at risk of fungal infections due to neutropenia caused by cytotoxic chemotherapy, radiotherapy, or bone marrow transplantation.
7. Skin fungal infections including hand and toenail mycosis, athlete's foot (tinea pedis), tinea corporis, jock itch (tinea groin), tinea versicolor, and cutaneous candidiasis.

3. Usage/Dosage
Dosage and usage
The route of drug administration is determined depending on the patient's clinical condition.
Because oral preparations are absorbed quickly and almost completely, the dosage for oral preparations (capsules, dry syrup) and injection preparations is the same.

[Adult]
1. Vaginal candidiasis: Single oral administration of 150 mg as fluconazole

2. Mucosal candidiasis
1) Oropharyngeal candidiasis: This drug is usually administered at 50 mg once a day for 7-14 days, and extended administration is possible at the doctor's discretion.
2) Chronic atrophic oral candidiasis (pain in the mouth caused by dentures): This drug is usually administered at 50 mg once a day for 14 days, and local disinfection of the dentures must be performed.
3) Other mucosal candidiasis (esophageal candidiasis excluding vaginal candidiasis, non-invasive bronchopulmonary infection, candiduria, mucocutaneous candidiasis, etc.): This drug is usually administered at 50 mg once a day for 14-30 days, and in case of refractory mucosal candidiasis, the dose can be increased to 100 mg once a day.

3. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive candidal infections (peritoneum, endocardium, lung, urinary system, etc.):
This drug is usually administered at a dose of 400 mg once on the first day and 200 mg once a day from the next day. Depending on the patient's response, the dose can be increased up to 400 mg once a day. The duration of administration is determined based on clinical response and medical judgment.

4. Cryptococcal meningitis and cryptococcosis in other areas: This drug is usually administered at 400 mg once on the first day and 200 to 400 mg once a day starting the next day. The duration of treatment is determined by clinical and mycological response, but usually should be administered for at least 6 to 8 weeks.

5. To prevent recurrence of cryptococcal meningitis in AIDS patients, administer 200 mg of this drug once a day indefinitely after the patient has received all basic treatment.

6. Prevention of fungal infections in immunocompromised patients at risk of fungal infections due to neutropenia caused by cytotoxic chemotherapy, radiotherapy, or bone marrow transplantation: Depending on the patient's risk of developing fungal infections, 50 to 400 mg of this drug should be administered once a day. For patients at very high risk of systemic fungal infection, i.e., patients who are expected to have severe neutropenia or a long period of neutropenia, such as in the case of bone marrow transplantation, 400 mg once daily is recommended. For these patients, 400 mg should be administered starting 5-6 days before neutropenia is expected to begin, and 400 mg should be continued for one week after the neutrophil count increases to over 1,000 cells/mm3.

7. For hand and toenail mycosis, administer 150 mg once a week until the hands and toenails grow again (until new uninfected hands and toenails grow). It usually takes 3-6 months for new fingernails to grow, and 6-12 months for toenails, and the growth rate may vary depending on the individual's age. Even after successful long-term treatment, hands and toenails sometimes remain damaged.
Skin fungal infections including athlete's foot (tinea pedis), tinea corporis, jock itch (tinea groin), and cutaneous candidiasis: This drug is usually administered at 50 mg once a day or 150 mg once a week for 2-4 weeks. However, in the case of athlete's foot, administration may be necessary for 6 weeks depending on the course. For tinnitus, administer 50 mg once a day for 2-4 weeks.

[Children]
Pediatric doses based on adult doses generally apply the following criteria and do not exceed a maximum of 400 mg.

Adult dosage Pediatric dosage
100 mg 3 mg/kg
200 mg 6 mg/kg
400 mg 12 mg/kg

However, safety and effectiveness for infants under 6 months of age have not been established (see precautions for use).
1. Oropharyngeal candidiasis
Administer this drug at 6 mg per kg of body weight on the first day, and 3 mg per kg of body weight once a day from the next day. It should be administered for at least 2 weeks to prevent recurrence.

2. Esophageal candidiasis
This drug is administered at 6 mg per kg of body weight on the first day, and from the next day onwards, 3 mg per kg of body weight is administered once a day. Depending on the patient's response, the dose may be increased up to 12 mg per kg of body weight once a day. Administer for at least 3 weeks and at least 2 weeks after symptoms disappear.

3. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive candidal infections (peritoneum, endocardium, lung, urinary system, etc.) Administer at a dose of 6-12 mg per kg of body weight once daily. The administration period is determined based on clinical response and medical judgment.

4. Cryptococcus meningitis
This drug is administered at 12 mg per kg of body weight on the first day, and from the next day, 6 mg per kg of body weight once a day. Depending on the patient's response, the dose may be increased to 12 mg per kg of body weight once a day. The treatment period is 10-12 weeks after a negative cerebrospinal fluid culture result.

5. To prevent recurrence of cryptococcal meningitis in AIDS patients, administer 6 mg per kg of body weight once a day after the patient has received all basic treatment.

6. For children with renal impairment, the dosing interval should be increased and the dose reduced according to the same standards as adult renal impairment patients, depending on the degree of renal impairment. When administering a dose of less than 10 mg, the syrup must be administered orally or the injection must be administered intravenously, depending on the clinical condition of the child, in order to obtain the correct amount.

[Elderly]
If renal function is normal, the adult dose is usually administered. In case of renal impairment (creatinine clearance less than 50 ml/min), the dose should be reduced or the interval between doses should be increased.

[Patients with renal impairment]
The drug is excreted unchanged primarily through urine. When administering only once, there is no need to adjust the dose, but when administering multiple times, administer the regular dose only on the first day of administration and adjust the dose as follows from the next day.

Creatinine clearance (mL/min) Recommended dosage
>50: 100% of the usual dose

< 50 (without dialysis) 50% of the usual dose

Patients receiving hemodialysis: 100% of the usual dose after each hemodialysis session.

For patients receiving regular dialysis, 100% of the usual dose should be administered after each dialysis session. On days when dialysis is not performed, the dose should be reduced according to the creatinine clearance rate.

4. Precautions for use
Precautions for use

1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug, other excipients, or other azole drugs
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients receiving the following drugs:
- Based on the results of the multiple-dose interaction study, this drug should be used in combination with terfenadine in patients receiving repeated doses of 400 mg or more per day.
- Concomitant use with drugs that prolong the QT interval and with cisapride, astemizole, erythromycin, pimozit, and quinidine, which are metabolized by CYP3A4
- Ergotamine, dihydroergotamine
4) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with a history of drug hypersensitivity reaction
2) Patients with renal impairment
3) Patients with liver failure (liver function may worsen)
4) Patients with the possibility of arrhythmia such as heart disease or electrolyte abnormalities (ventricular tachycardia including torsade de pointes, QT prolongation, ventricular fibrillation, atrioventricular block, bradycardia, etc. may occur).
5) Patients receiving the following drugs:
- Patients receiving this drug in combination with terfenadine in doses less than 400 mg per day should be carefully monitored.
- Halophantrine
6) This drug is a strong CYP2C9 and CYP2C19 inhibitor and a moderate CYP3A4 inhibitor. Therefore, patients should be monitored when coadministered with drugs with a narrow therapeutic window that are metabolized via CYP2C9, CYP2C19 and CYP3A4.

3. Adverse reactions
This drug is generally well tolerated.
During clinical trials administering this drug and a reference drug, changes in renal and hematological function test results and liver dysfunction were observed, especially in some patients with serious underlying diseases such as AIDS or cancer, but the clinical significance and causal relationship with treatment are not clear.
During treatment with this drug, the following adverse reactions were observed and reported with the following frequency:
[Refer to attached document for details]

pediatric patient
The patterns and frequencies of adverse events and laboratory abnormalities recorded in pediatric clinical trials are similar to those seen in adults.

4. General precautions
1) In particular, in some patients with serious underlying diseases such as AIDS or cancer, abnormalities were observed in hematology, liver, kidney, and other biochemical function tests while taking this drug, but their clinical significance and relationship with this drug were not confirmed.
2) In very rare cases, liver necrosis was observed in the autopsy of a patient with a serious underlying disease who had taken this drug several times. Although these patients had diseases that could cause liver necrosis or were taking multiple drugs with the potential to cause hepatotoxicity, a relationship with this drug cannot be ruled out. Therefore, if the liver enzymes of these patients significantly increase during treatment, the risks and benefits of administering this drug must be carefully evaluated.
3) AIDS patients are prone to severe skin reactions to many drugs. An increase in such skin reactions has been observed in a small number of AIDS patients following combined administration of this drug with other drugs known to be associated with severe epidermal desquamation.
4) When administering to patients with renal impairment, exercise caution by measuring creatinine clearance before administration and adjusting the dosage and administration interval.
5) It is recommended to conduct blood tests, renal function tests, liver function tests, and blood electrolyte tests before administering this drug.
6) Adrenal dysfunction has been reported in patients receiving this drug.
7) Some azole drugs, including this drug, have been associated with prolongation of the QT interval on electrocardiograms.
This drug causes QT prolongation by inhibiting rectifier potassium channel current (Ikr). QT prolongation caused by other drugs (e.g., amiodarone) may be enhanced through cytochrome P450 3A4 inhibition. During post-marketing surveillance, very rare cases of QT prolongation and torsade de pointes occurred in patients taking this drug. These reports included patients with severe disease who had confounding risk factors such as structural heart disease, electrolyte abnormalities, and the use of concomitant medications that may have an effect. Patients with hypokalemia and advanced heart failure are at high risk for life-threatening ventricular arrhythmias and torsade de pointes.
Caution should be exercised when administering this drug to patients at risk for potential arrhythmias.
8) Studies have shown that infections with Candida species other than C. albicans are increasing. Candida species may have intrinsic resistance to fluconazole (e.g. C. kruseiand and C. auris) or may have low susceptibility. These infections may require secondary alternative antifungal treatments if treatment fails. Therefore, the prevalence due to the development of resistance in various Candida species must be considered.

5. Interaction
1) Do not administer this drug and the following drugs together.
(1) Cisapride: Cardiovascular adverse reactions, including torsade de pointes, were reported when this drug and cisapride were administered together. In a controlled clinical trial of co-administration of this drug (200 mg once daily) and cisapride (20 mg four times daily), increased plasma concentrations of cisapride and prolongation of the QTc interval were observed. Therefore, do not administer this drug and cisapride together.
(2) Terfenadine: Because severe cardiac arrhythmia due to QTc interval prolongation occurred in patients receiving azole antifungal drugs together with terfenadine, a drug interaction test was conducted. A trial using 200 mg per day of this drug did not demonstrate QTc interval prolongation. Another trial (administration of 400 mg per day or 800 mg per day of this drug) showed that when terfenadine was co-administered, administration of 400 mg or more of this drug per day significantly increased the blood concentration of terfenadine. Do not co-administer terfenadine with doses of 400 mg or more.
(3) Astemizole: Concomitant use of this drug and astemizole may reduce the clearance of astemizole. Increased plasma concentrations of astemizole may cause QT prolongation and, rarely, torsade de pointes. Do not administer this drug and astemizole together.
(4) Pimojit: Although in vivo and in vitro tests have not been conducted, co-administration of this drug and Pimojit may cause metabolic inhibition of Pimojit. Increased pimogit plasma concentrations may cause QT prolongation and, rarely, torsade de pointes. This drug and pimogit should not be administered together.
(5) Quinidine: Although in vivo and in vitro experiments have not been conducted, co-administration of this drug and quinidine may cause inhibition of quinidine metabolism. Quinidine administration has been associated with QT prolongation and, rarely, torsade de pointes. This drug and quinidine should not be administered together.
(6) Erythromycin: The combined use of this drug and erythromycin may increase the risk of cardiotoxicity (QT interval prolongation, Torsade de Pointes) and subsequent sudden cardiac arrest. This drug and erythromycin should not be administered together.
2) When administering this drug and the following drugs together, administer with caution.
(1) Amiodarone: Coadministration of this drug and amiodarone may increase QT prolongation. If co-administration of this drug and amiodarone is necessary, caution is required, especially at high doses (800 mg) of this drug.
3) When administering this drug and the following drugs together, careful administration and dose adjustment should be considered.
How other drugs affect fluconazole
(1) Hydrochlorothiazide: In a pharmacokinetic interaction study conducted on healthy volunteers, when this drug was co-administered with multiple doses of hydrochlorothiazide, the plasma concentration of this drug increased by up to 40%. Due to this level of effect, no dosage adjustment of this drug is necessary in patients taking concomitant diuretics.
(2) Rifampicin: When this drug and rifampicin were administered together, the AUC of this drug decreased by 25% and the half-life was shortened by 20%. Therefore, an increase in the dose of this drug should be considered when used in combination with rifampicin.
How fluconazole affects other drugs
This drug is a strong CYP2C9 and CYP2C19 inhibitor and a moderate CYP3A4 inhibitor. In addition to the observed/proven interactions noted below, there is a risk of increased plasma concentrations of other drugs metabolized by CYP2C9, CYP2C19 and CYP3A4 when coadministered with this drug. Therefore, caution is required when using in combination with the following drugs, and patients must be carefully monitored. Because of the drug's long half-life, the enzyme inhibitory effect of fluconazole persists for 4-5 days even after treatment is discontinued.
(1) Alfentanil: In a study in which this drug and alfentanil were co-administered, an increase in the half-life of alfentanil and a decrease in clearance and distribution volume were observed. The possibility of this action lies in the drug's CYP3A4 inhibition. Dosage adjustment of alfentanil may be necessary.
(2) Amitriptyline, nortriptyline: This drug increases the effects of amitriptyline and nortriptyline. 5-nortriptyline/5-amitriptyline can be measured at the start of combination treatment with this drug and one week later. The dose of amitriptyline/nortriptyline should be adjusted if necessary.
(3) Amphotericin B: When this drug and amphotericin B were administered simultaneously to normal mice and immunosuppressed mice under infection, the following results were shown: slightly more antifungal effect was observed in systemic infection by Candida albicans, no drug interaction was observed in intracranial infection by Cryptococcus neoformans, and antagonistic effect of the two drugs in systemic infection by Aspergillus fumigatus. The clinical significance of the results obtained in this study is unknown.
(4) Anticoagulant: In a drug interaction test on healthy men, this drug increased prothrombin time (12%) after warfarin administration. In post-marketing experience, similar to other azole drugs, bleeding tendencies (bruising, nosebleeds, gastrointestinal bleeding, hematuria, hematochezia) due to prolongation of prothrombin time were reported when this drug and warfarin were administered together. Prothrombin time should be carefully monitored in patients receiving coumarin anticoagulants or indenedione anticoagulants. Dosage adjustment of these anticoagulants may be necessary.
(5) Azithromycin: In an open-label, randomized, three-way crossover study in 18 healthy volunteers, the effect of azithromycin (1200 mg single oral dose) on the pharmacokinetics of this drug (800 mg single oral dose) as well as the effect of this drug on the pharmacokinetics of azithromycin were evaluated. There were no significant pharmacokinetic interactions between this drug and azithromycin.
(6) Benzodiazepine drugs (short-acting): After midazolam administration, the concentration and psychomotor effects of midazolam were significantly increased by this drug. This effect was more pronounced with the oral version of this drug than with the injectable version. If concurrent use of this drug and benzodiazepine drugs is necessary, a reduction in benzodiazepine drugs should be considered, and patients should be appropriately monitored.
Because this drug inhibits the metabolism of triazolam, it increases the AUC of triazolam (single dose) by approximately 50%, Cmax by 20-32%, and half-life by 25-50%. Dosage adjustment of triazolam may be necessary.
(7) Carbamazepine: This drug inhibits the metabolism of carbamazepine, and a 30% increase in carbamazepine serum concentration was observed. There is a risk of carbamazepine toxicity. Depending on the concentration/effect, the dosage of carbamazepine may need to be adjusted.
(8) Calcium channel blockers: Certain calcium channel blockers (nifedipine, isradipine, amlodipine, verapamil, felodipine) are metabolized by CYP3A4. This drug has the potential to increase systemic exposure to calcium channel blockers. Frequent monitoring for adverse reactions is recommended.
(9) Celecoxib: When combined treatment with this drug (200 mg per day) and celecoxib (200 mg), the Cmax and AUC of celecoxib increased by 68% and 134%, respectively. When coadministered with this drug, the dose of celecoxib may need to be reduced by half.
(10) Cyclosporine: This drug significantly increases the AUC and concentration of cyclosporine. Depending on the concentration of cyclosporine, it can be used together with this drug by reducing the dosage of cyclosporine.
(11) Cyclophosphamide: Increases in serum bilirubin and serum creatinine were observed during combined therapy with this drug and cyclophosphamide. When careful consideration is given to the risk of increased serum bilirubin and serum creatinine, it may be used in combination with this drug.
(12) Fentanyl: One fatal case of a possible interaction between this drug and fentanyl has been reported. It was determined that the death was due to fentanyl intoxication. Furthermore, a randomized, crossover trial in 12 healthy volunteers showed that the drug significantly delayed fentanyl elimination. Elevated concentrations of fentanyl may cause respiratory depression.
(13) Halofantrine: This drug may increase the plasma concentration of halofantrine due to its inhibitory effect on CYP3A4.
(14) HMG-CoA reductase inhibitors: When this drug is co-administered with HMG-CoA reductase inhibitors that are metabolized by CYP2C9 (e.g. fluvastatin) or by CYP3A4 (e.g. atorvastatin, simvastatin), the risk of myopathy and rhabdomyolysis increases. If combination therapy is necessary, patients should be observed for symptoms of myopathy and rhabdomyolysis, and creatine kinase should be monitored. If myopathy/rhabdomyolysis is diagnosed or suspected or a significant increase in creatine kinase is observed, HMG-CoA reductase inhibitor treatment should be discontinued.
(15) Losartan: During the treatment period, this drug prevents losartan from being metabolized into its active metabolite (E-31 74), which is responsible for most of the angiotensin II receptor antagonism. Patients should continue to monitor their blood pressure.
(16) Methadone: This drug may increase serum concentrations of methadone. Dosage adjustment of methadone may be necessary.
(17) Nonsteroidal anti-inflammatory drugs (NSAIDs): Compared with flurbiprofen alone, coadministration with this medicine increased flurbiprofen Cmax and AUC by 23% and 81%, respectively. Similarly, compared with racemic ibuprofen (400 mg) alone, coadministration increased the Cmax and AUC of the pharmacologically active isomer, S-(+)-ibuprofen, by 15% and 82%, respectively.
Although not specifically studied, this drug has the potential to increase systemic exposure of other NSAIDs metabolized by CYP2C9 (e.g., naproxen, lonoxicam, meloxicam, diclofenac). Frequent monitoring for adverse reactions and NSAID-related toxicities is recommended. Dosage adjustment of NSAIDs may be necessary.
(18) Olaparib: Moderate CYP3A4 inhibitors such as this drug increase the plasma concentration of olaparib, so co-administration is not recommended. If co-administration cannot be avoided, the olaparib dosage is limited to 200 mg twice daily.
(19) Oral contraceptives: Two pharmacokinetic studies were conducted on multiple doses of fluconazole in combination with oral contraceptives. When administered at 200 mg of this drug per day, the AUC of ethinyl estradiol and levonorgesterol increased by 40% and 24%, respectively, whereas there was no effect on hormone levels in a study in which 50 mg of this drug was administered. Therefore, administration of multiple doses of fluconazole, such as the above dose, does not appear to affect the efficacy of oral contraceptives.
(20) Phenytoin: This drug inhibits the hepatic metabolism of phenytoin. When coadministered with this drug, serum concentrations of phenytoin should be monitored to avoid phenytoin toxicity.
(21) Prednisolone: A case of acute adrenal cortical dysfunction was reported in a liver transplant patient receiving prednisolone when the drug was discontinued after 3 months of treatment. It is expected that discontinuation of this drug may result in increased activity of CYP3A4, resulting in increased metabolism of prednisolone. Patients receiving this drug and prednisolone for long periods of time should be carefully monitored for hypoadrenocortical function when this drug is discontinued.
(22) Rifabutin: There was an interaction report that the serum concentration of rifabutin increased by up to 80% when this drug was used together with rifabutin. Uveitis has been reported in patients receiving this drug in combination with rifabutin. Patients should be carefully monitored when coadministering this drug with rifabutin.
(23) Saquinavir: This drug increases the AUC and Cmax of saquinavir by approximately 50% and approximately 55%, respectively, and reduces the clearance of saquinavir by approximately 50% by inhibiting P-glycoprotein and hepatic metabolism of saquinavir by CYP3A4. Dosage adjustment of saquinavir may be necessary.
(24) Sirolimus: This drug increases the plasma concentration of sirolimus, possibly by inhibiting the metabolism of sirolimus through CYP3A4 and P-glycoprotein. Sirolimus can be used in combination with this drug, considering dose adjustment of sirolimus according to effectiveness/concentration measurements.
(25) Sulfonylureas: The serum half-life of sulfonylureas (e.g., chlorpropamide, glibenclamide, glipizide, tolbutamide) was shown to be prolonged when co-administered with this drug in healthy volunteers. During concurrent administration of this drug and sulfonylurea drugs, frequent monitoring of blood sugar and appropriate reduction of sulfonylurea drugs are recommended.
(26) Tacrolimus: This drug increases the serum concentration of orally administered tacrolimus by up to 5 times by inhibiting the metabolism of tacrolimus by CYP3A4 in the intestine. No significant pharmacokinetic changes were observed when tacrolimus was administered intravenously. Increased concentrations of tacrolimus are associated with nephrotoxicity. Depending on the concentration of tacrolimus, the dose of orally administered tacrolimus should be reduced.
(27) Theophylline: In a placebo-controlled interaction study, the average plasma clearance of theophylline decreased by 18% when 200 mg of this drug was administered for 14 days. Patients receiving high doses of theophylline or at increased risk of theophylline toxicity should be observed for signs of theophylline toxicity while taking this drug, and if signs of toxicity appear, the treatment method should be appropriately modified.
(28) Tofacitinib: When tofacitinib is coadministered with drugs that have a moderate CYP3A4 inhibitory effect and a CYP2C19 inhibitory effect (e.g. fluconazole), the exposure of tofacitinib is increased. Dosage adjustments to tofacitinib may be necessary.
(29) Vinca alkaloid drugs: Although not studied, this drug may increase the plasma concentration of vinca alkaloid drugs (e.g. vincristine, vinblastine) and cause nephrotoxicity due to its potential to inhibit CYP3A4.
(30) Vitamin A: Cases reported in patients receiving concomitant treatment with this drug and any trans-retinoic acid (the acidic form of vitamin A) resulted in an unintended adverse reaction related to the central nervous system (CNS) of pseudotumor cerebri, which disappeared after discontinuation of treatment with this drug. It should be borne in mind that concomitant use of this drug may cause adverse reactions related to the central nervous system.
(31) Zidovudine: As this drug reduces the clearance of oral zidovudine by approximately 45%, it increases the Cmax and AUC of zidovudine by 84% and 74%, respectively. The half-life of zidovudine is extended by approximately 128% after coadministration with this drug. Patients receiving zidovudine concomitantly with this drug should be monitored for the development of zidovudine-related adverse reactions. A reduction in zidovudine may be considered.
(32) Endogenous steroids: Administration of 50 mg of this drug per day did not affect the endogenous steroid concentration in women. Dosing of 200 to 400 mg per day had no effect on adrenocorticotropic hormone stimulation responses or endogenous steroid concentrations in healthy male volunteers.
(33) Voriconazole (CYP2C9, CYP2C19, CYP3A4 inhibitor): oral formulation of this drug (400 mg on the first day, then 200 mg every 24 hours for 4 days) and oral voriconazole (400 mg every 12 hours on the first day, then 200 mg every 12 hours for 2.5 days) were administered to 8 healthy male subjects. When administered in combination, the Cmax and AUCτ of voriconazole increased by 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively, on average. In subsequent clinical trials involving eight healthy male subjects, reducing the dose and/or frequency of administration of voriconazole and fluconazole did not eliminate or reduce these effects. Co-administration of this drug and voriconazole is not recommended at any dose.
An interaction study showed that no clinically significant malabsorption of this drug occurred when the oral drug was administered in combination with food, cimetidine, antacids, or total body radiotherapy for bone marrow transplantation.
Prescribers should be aware that interactions may occur with this drug and other drugs for which interaction studies have not been performed.

6. Administration to pregnant and lactating women
1) Pregnant women
Women of childbearing potential should consider effective contraception and should do so while taking this medicine and for approximately 1 month after the last dose.
Spontaneous abortion and congenital abnormalities in infants have been reported in pregnant women who administered 150 mg of this drug once or repeatedly during the first three months of pregnancy.
Multiple congenital malformations have been reported in infants of pregnant women who received high doses of fluconazole (400-800 mg per day) for 3 months or more for coccidioidomycosis.
The relationship between the use of fluconazole and the occurrence of these side effects is unclear. In animals, side effects on the fetus were confirmed only at doses high enough to cause maternal toxicity. Doses of 5 mg/kg or 10 mg/kg had no effect on the fetus. At doses of 25 mg/kg, 50 mg/kg and higher, increased fetal anatomical deformities (excessive ribs and renal pelvis dilatation) and delayed ossification were observed. In the dose range of 80 mg/kg (approximately 20-60 times the recommended human dose) - 320 mg/kg, there was increased embryolethality in rats and fetal abnormalities including corrugated ribs, cleft palate, and abnormal craniofacial ossification. These effects are the same when inhibiting estrogen synthesis in rats, and may be due to the already known consequences of lowering estrogen concentrations during pregnancy, organ development, and parturition.
A case report describes the development of a prominent and rare form of birth defects in an infant of a pregnant woman who received high doses of fluconazole (400 to 800 mg per day) during all or most of the first trimester of pregnancy. Characteristics found in these infants include: Flat head, abnormal face, abnormal development of the skull bone, cleft palate, femoral bowing, thin ribs, long bones, arthrogryposis, congenital heart disease.
Administration of this drug to pregnant women should be avoided.
2) Nursing mothers
This drug has been found in breast milk at concentrations similar to those in plasma. Therefore, this drug is not administered to nursing mothers.

7. Administration to children
The safety and effectiveness of this drug in infants under 6 months of age have not been established. However, there is data showing that this drug has been used safely in a small number of infants (29 children aged 1 day to 6 months), so this drug is administered only when it is judged absolutely necessary.

8. Effects on ability to drive and operate machinery
Be careful when driving or operating machinery as dizziness and seizures may occasionally occur.

9. Treatment in case of overdose
1) There have been reports of hallucinations and paranoid behavior when taking an overdose of this drug.
2) In case of overdose, symptomatic treatment (supportive treatment and gastric lavage if necessary) may be appropriate.
3) This drug is mostly excreted through urine, so increasing the amount of urine will increase the excretion rate of this drug. After 3 hours of hemodialysis, plasma concentration decreases by almost 50%.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 capsules/bottle

7. Expiration date
36 months from date of manufacture

Product Updates

Total 3items

No.Product NameDetailsDate of ChangeDownload
3Lucozol Cap.Precautions for use2021.03.29HWPContents of permit change order (including change comparison table).hwp
2Lucozol Cap.Lucozol Capsule (Dosage, Instructions for Use)2018.03.26HWPFluconazole single oral agent_50mg unified adjustment plan.hwp
1Lucozol Cap.Lucozol Capsule (Dosage, Precautions for Use)2014.11.19HWPLucosol Capsule Usage Dosage_Precautions for Use.hwp